NCT05436886View on ClinicalTrials.gov

Bioequivalence Study of Neurogabin-M (Gabapentin 400 mg) Capsule With Parketin (Gabapentin 400 mg) Capsules

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 28, 2013

Primary Completion Date

July 5, 2013

Study Completion Date

September 10, 2013

Conditions
Healthy VolunteersBioequivalence Study
Interventions
DRUG

Neurogabin (Gabapentin) 400 mg capsule

All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.

DRUG

Parketin (Gabapentin) 400 mg capsule

All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.

Trial Locations (1)

75270

Center for Bioequivalence Studies and clinical research (CBSCR), ICCBS, Karachi

All Listed Sponsors
collaborator

Merck Pvt. Ltd, Pakistan

UNKNOWN

collaborator

Center for Bioequivalence Studies and Clinical Research

OTHER

lead

University of Karachi

OTHER

NCT05436886 - Bioequivalence Study of Neurogabin-M (Gabapentin 400 mg) Capsule With Parketin (Gabapentin 400 mg) Capsules | Biotech Hunter | Biotech Hunter